Bento et al. [22] reported that treatments with some SPMs (RvD1, RvD2, and 17R-HDHA) were effective in preventing gut inflammation in experimental mice models of colitis, reducing colonic cytokine levels of TNF-α, IL-1β, and other inflammatory markers. The gene discussed is TNF; the disease is colitis.